Latest News about NVS
Recent news which mentions NVS
From Benzinga
Emergent BioSolutions Soars: Analyst Upgrades Stock With Near 100% Upside After FDA's Positive Move
April 10, 2023
From Benzinga
From Benzinga
6 Questions With Rocket Pharma's CEO On World Health Day: How The Biotech Is 'Changing The Narrative'
April 07, 2023
From Benzinga
7 Very Undervalued Penny Stocks to Buy in April 2023
April 06, 2023
From InvestorPlace
From Motley Fool
Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 27, 2023
From Benzinga
From Benzinga
From Benzinga
Why Novartis Shares Are Trading Higher Premarket Today
March 27, 2023
From Benzinga
First Citizens shares leap on SVB deal as Novartis stock boosted by breast-cancer drug trial
March 27, 2023
From MarketWatch
First Republic Bank, KeyCorp And Other Big Stocks Moving Higher In Monday's Pre-Market Session
March 27, 2023
From Benzinga
2 Biotech Stocks That Could Make You Richer
March 21, 2023
From Motley Fool
From Benzinga
Novartis Reveals Long-Term Data Of Atrophy Gene Therapy Exhibiting Sustained Durability Of Up To 7.5 Years
March 20, 2023
Tickers
NVS
From Benzinga
FDA Approves Novartis' Tafinlar + Mekinist For Pediatric Brain Cancer With Certain Mutations
March 17, 2023
Tickers
NVS
From Benzinga
From Benzinga
Novartis' Prostate Cancer Therapy Hit By Supply Crunch, Seeks To Ramp Up Production To Ease Supply Issues
March 16, 2023
Tickers
NVS
From Benzinga
From InvestorPlace
From Benzinga
4 AI Stocks That Are Revolutionizing Healthcare
March 06, 2023
From InvestorPlace
This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine's Next Frontier?
March 03, 2023
From Benzinga
From MarketWatch
Novartis Takes Down $80M NASH Pact With Pliant Therapeutics
February 24, 2023
From Benzinga
Better Buy: Beam Therapeutics or Intellia Therapeutics?
February 22, 2023
From Motley Fool
This chart gives one reason European stocks may continue to outperform U.S. equities
February 17, 2023
From MarketWatch
Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path
February 14, 2023
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.